• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Abbott’s FreeStyle Libre wins reimbursement in Japan

August 31, 2017 By Sarah Faulkner

AbbottAbbott (NYSE:ABT) said today that the Ministry of Health Labor and Welfare in Japan has granted national reimbursement for the company’s FreeStyle Libre glucose monitoring system.

The FreeStyle Libre system uses a small sensor worn on the back of the upper arm to measure glucose every minute in interstitial fluid through a filament inserted under the skin. Abbott said its system can produce a glucose reading painlessly in less than 1 second by scanning a reader over the sensor.

“This is a significant development for the Japanese diabetes community – both for the people living with the condition and for their healthcare professionals,” Jared Watkin, SVP of Abbott’s Diabetes Care division, said in prepared remarks. “FreeStyle Libre has had a demonstrable impact around the world in helping people with diabetes, and we are pleased with the MHLW decision to make the product available through government reimbursement to those who need it.”

In February,  Abbott touted results from real-world use data for its FreeStyle Libre system. The data showed that people using its technology to monitor their glucose levels spend less time in hypoglycemia or hyperglycemia and have improved average glucose levels.

“For people living with diabetes frequent glucose measurement is key to effective diabetes management. It is often challenging for my patients to comply with glucose testing because of the pain, inconvenience and stigma of using finger sticks,” Dr. Yoshihito Atsumi, director of the Diabetes Center at Eiju General Hospital, added. “FreeStyle Libre not only enables my patients to check their glucose more frequently due to the convenience of the technology, but it also provides valuable glucose trends and patterns to help me make more informed treatment decisions.”

Japan’s decision puts the country in a group with 16 others that have partially or fully covered FreeStyle Libre, including France and Germany. The system is being reviewed by the FDA in the U.S.

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Diabetes, Featured, Regulatory/Compliance, Wall Street Beat Tagged With: abbott

IN CASE YOU MISSED IT

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS